Overview


According to FutureWise analysis the market for neonatal seizures drugs in 2023 is US$ 0.24 billion, and is expected to reach US$ 0.31 billion by 2031 at a CAGR of 3.62%.

Seizures are abnormal electrical discharges in the central nervous system that generally manifest as stereotyped muscular activity or autonomic abnormalities in newborns. Electroencephalography verifies the diagnosis, and more testing is required for reasons. Up to 1.4 percent of full-term newborns and 20% of premature babies suffer from seizures. Seizures could be a sign of a serious newborn illness that requires immediate attention. Because neonates lack myelination and have insufficient dendrites and synapses, electrical activity does not transmit, hence most neonatal seizures are focal. Doctors face significant challenges when treating children with epilepsy due to limited information available to help determine the appropriate use of medications for children of all ages with various kinds of epilepsy.

However, research into how antiepileptic medications (AEDs) can be used to treat newborn seizures and infantile spasms, which are seizure disorders that occur in the first year of life, has recently progressed. The effectiveness of AEDs in treating these conditions has been questioned, and predicting the outcome of these issues for each child has been difficult, so any progress is welcome. Hypoxia-ischemia is becoming more common, increased prevalence of hypoxia-ischemia is expected to have an impact on the growth of the newborn seizures medicines market. Hypoxia-ischemia, which can occur before, during, or after delivery, is the most common cause of neonatal seizures. These seizures can be severe and difficult to treat, but they normally pass in 3 to 4 days. When new-born hypoxia is treated with therapeutic hypothermia (usually whole-body cooling), seizures may be less severe, although they may recur after rewarming.

Additionally, Infections in newborns are becoming more common the rising incidences of newborn infections are likely to boost the market's growth rate. Seizures can occur as a result of newborn diseases such as meningitis and sepsis; seizures are generally accompanied by other symptoms and signs in these circumstances. The most prevalent causes of infection in neonates are group B streptococci and gram-negative bacteria. Encephalitis caused by the cytomegalovirus, herpes simplex virus, rubella virus, Treponema pallidum, Toxoplasma gondii, or Zika virus can potentially induce seizures. The market for neonatal seizures medications will grow as more public and private groups take steps to raise awareness.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Neonatal Seizures Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Neonatal Seizures Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Merck KGaA
  • Eisai Co., Ltd.
  • AstraZeneca
  • Sanofi
  • Novartis AG
  • Abbott
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Wockhardt
  • Novo Nordisk A/S
  • Glenmark Pharmaceuticals Limited
  • Cipla Inc.
  • Bausch Health Companies Inc.
  • Otsuka America Pharmaceutical, Inc.
  • Johnson and Johnson Private Limited
  • Takeda Pharmaceutical Company Limited
  • Sumitomo Corporation
  • Biocon

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Type

  • Tonic Seizures
  • Clonic and Myoclonic Seizures
  • Non Paroxysmal Repetitive Behaviours

By Drug

  • Dilantin
  • Phenobarbital
  • Other

By Dosage

  • Injection
  • Tablets
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Others

By End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Neonatal Seizures Drugs Market By Type, By Drug, By Dosage, By Route of Administration, By End-Users, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Neonatal Seizures Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Neonatal Seizures Drugs Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Neonatal Seizures Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Neonatal Seizures Drugs Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Tonic Seizures
        2. Clonic and Myoclonic Seizures
        3. Non Paroxysmal Repetitive Behaviours

  • 8.   Neonatal Seizures Drugs Market, By Drug Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Dilantin
        2. Phenobarbital
        3. Other

  • 9.   Neonatal Seizures Drugs Market, By Dosage Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Injection
        2. Tablets
        3. Others

  • 10.   Neonatal Seizures Drugs Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Parenteral
        3. Others

  • 11.   Neonatal Seizures Drugs Market, By End-Users Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Specialty Clinics
        3. Homecare
        4. Others

  • 12.   Neonatal Seizures Drugs Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy
        4. Others

  • 13.   North America Neonatal Seizures Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 14.   Latin America Neonatal Seizures Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 15.   Europe Neonatal Seizures Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 16.   Asia Pacific Neonatal Seizures Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 17.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 18.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 19.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Merck KGaA
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Eisai Co., Ltd.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. AstraZeneca
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Sanofi
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Novartis AG
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Abbott
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview 
        7. F. Hoffmann-La Roche Ltd.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Teva Pharmaceutical Industries Ltd.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Pfizer Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. GlaxoSmithKline plc
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Wockhardt
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview    
        12. Novo Nordisk A/S
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Glenmark Pharmaceuticals Limited
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Cipla Inc.
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Bausch Health Companies Inc.
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Otsuka America Pharmaceutical, Inc.
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Johnson & Johnson Private Limited
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Takeda Pharmaceutical Company Limited
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. Sumitomo Corporation
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview
        20. Biocon
                20.1. Company Overview
                20.2. Product Portfolio
                20.3. SWOT Analysis
                20.4. Financial Overview
                20.5. Strategic Overview

  • 20.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 21.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients